These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 8126385)
1. [Urokinase-type plasminogen activator as a predictor for lymph nodes metastasis of uterine cervical cancer]. Fujishiro S; Kobayashi H; Terao T Nihon Sanka Fujinka Gakkai Zasshi; 1994 Feb; 46(2):129-36. PubMed ID: 8126385 [TBL] [Abstract][Full Text] [Related]
2. Impact of urokinase-type plasminogen activator and its inhibitor type 1 on prognosis in cervical cancer of the uterus. Kobayashi H; Fujishiro S; Terao T Cancer Res; 1994 Dec; 54(24):6539-48. PubMed ID: 7987854 [TBL] [Abstract][Full Text] [Related]
4. Biochemical markers as a predictor for lymph-node involvement in patients with cervical-cancer of the uterus. Kobayashi H; Fujishiro S; Terao T Int J Oncol; 1994 May; 4(5):1053-9. PubMed ID: 21567019 [TBL] [Abstract][Full Text] [Related]
5. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647 [TBL] [Abstract][Full Text] [Related]
6. [Expression and significance of the urokinase-type plasminogen activator and its inhibitors in squamous cell carcinoma of human larynx]. Zhao EM; Han DM; Yu ZK; Fan EZ; Li Y Zhonghua Er Bi Yan Hou Ke Za Zhi; 2003 Feb; 38(1):39-42. PubMed ID: 12778766 [TBL] [Abstract][Full Text] [Related]
7. Tumour-associated fibrinolysis: the prognostic relevance of plasminogen activators uPA and tPA in human breast cancer. Schmitt M; Jänicke F; Graeff H Blood Coagul Fibrinolysis; 1990 Dec; 1(6):695-702. PubMed ID: 2133250 [TBL] [Abstract][Full Text] [Related]
8. Prognostic impact of stromal cell-derived urokinase-type plasminogen activator in gastric carcinoma. Okusa Y; Ichikura T; Mochizuki H Cancer; 1999 Mar; 85(5):1033-8. PubMed ID: 10091785 [TBL] [Abstract][Full Text] [Related]
9. [Urokinase-type plasminogen activator (uPA), uPA receptor (uPA-R) and inhibitors (PA I -1) expression in hepatocellular carcinoma in relation to cancer invasion/metastasis and prognosis]. Zheng Q; Tang Z; Wu Z Zhonghua Zhong Liu Za Zhi; 1998 Jan; 20(1):57-9. PubMed ID: 10921061 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Cozzi PJ; Wang J; Delprado W; Madigan MC; Fairy S; Russell PJ; Li Y Hum Pathol; 2006 Nov; 37(11):1442-51. PubMed ID: 16949925 [TBL] [Abstract][Full Text] [Related]
11. Tissue distribution of soluble and receptor-bound urokinase in human breast cancer using a panel of monoclonal antibodies. Carriero MV; Franco P; Del Vecchio S; Massa O; Botti G; D'Aiuto G; Stoppelli MP; Salvatore M Cancer Res; 1994 Oct; 54(20):5445-54. PubMed ID: 7923178 [TBL] [Abstract][Full Text] [Related]
12. In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. Bhuvarahamurthy V; Schroeder J; Denkert C; Kristiansen G; Schnorr D; Loening SA; Jung K; Staack A Oncol Rep; 2004 Oct; 12(4):909-13. PubMed ID: 15375521 [TBL] [Abstract][Full Text] [Related]
13. Clinical relevance of urokinase-type plasminogen activator, its receptor, and its inhibitor type 1 in endometrial cancer. Tecimer C; Doering DL; Goldsmith LJ; Meyer JS; Abdulhay G; Wittliff JL Gynecol Oncol; 2001 Jan; 80(1):48-55. PubMed ID: 11136569 [TBL] [Abstract][Full Text] [Related]
14. Localization of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans. Grøndahl-Hansen J; Ralfkiaer E; Kirkeby LT; Kristensen P; Lund LR; Danø K Am J Pathol; 1991 Jan; 138(1):111-7. PubMed ID: 1702928 [TBL] [Abstract][Full Text] [Related]
15. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer]. Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120 [TBL] [Abstract][Full Text] [Related]
16. Expression of urokinase plasminogen activator and its receptor in advanced epithelial ovarian cancer patients. Wang L; Madigan MC; Chen H; Liu F; Patterson KI; Beretov J; O'Brien PM; Li Y Gynecol Oncol; 2009 Aug; 114(2):265-72. PubMed ID: 19450871 [TBL] [Abstract][Full Text] [Related]
17. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Hildenbrand R; Schaaf A Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473 [TBL] [Abstract][Full Text] [Related]
18. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis. Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865 [TBL] [Abstract][Full Text] [Related]
19. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer. Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981 [TBL] [Abstract][Full Text] [Related]
20. Differential expression of urokinase-type plasminogen activator (uPA), its receptor (uPA-R), and inhibitor type-2 (PAI-2) during differentiation of keratinocytes in an organotypic coculture system. Schaefer BM; Stark HJ; Fusenig NE; Todd RF; Kramer MD Exp Cell Res; 1995 Oct; 220(2):415-23. PubMed ID: 7556451 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]